Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-κB pathway.

MLA

Liu, Zixu, et al. “Norcantharidin Liposome Emulsion Hybrid Delivery System Enhances PD-1/PD-L1 Immunotherapy by Agonizing the Non-Canonical NF-ΚB Pathway.” International Journal of Pharmaceutics, vol. 628, Nov. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ijpharm.2022.122361.

APA

Liu, Z., Zhao, L., Liu, H., Dong, N., Zhou, N., Zhang, Y., Yin, T., He, H., Gou, J., Tang, X., Yang, L., & Gao, S. (2022). Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-κB pathway. International Journal of Pharmaceutics, 628, N.PAG. https://doi.org/10.1016/j.ijpharm.2022.122361

Chicago

Liu, Zixu, Linxuan Zhao, Hao Liu, Nan Dong, Ning Zhou, Yu Zhang, Tian Yin, et al. 2022. “Norcantharidin Liposome Emulsion Hybrid Delivery System Enhances PD-1/PD-L1 Immunotherapy by Agonizing the Non-Canonical NF-ΚB Pathway.” International Journal of Pharmaceutics 628 (November): N.PAG. doi:10.1016/j.ijpharm.2022.122361.